The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; 17 of the 39 sources its claims cite were checked for support.
Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials
Open accessPreprint — published as 10.1007/s40265-023-01841-4 · Paper page
Abstract
Abstract Background Berberine is a nutraceutical that may improve lipid profiles. Berberine may also affect sex hormones and exert sex-specific effects, which has been overlooked. Objectives To comprehensively review the efficacy and safety of lipid-lowering effect of berberine with consideration of potential sex disparity. Methods Eligible studies were randomized controlled trials in adults that compared berberine versus placebo and measured blood lipids or lipoproteins. Studies were identified from Medline, Embase, Wanfang, CNKI, two clinical trial registries and previous systematic reviews. Mean differences (MD) were estimated using inverse variance weighting with random effects models. Risk of bias was assessed using the Cochrane risk of bias tool for randomized trials. Results 16 studies were included with treatment of 4 to 24 weeks. Berberine reduced low-density lipoprotein (LDL) cholesterol (−0.45 mmol/L, 95% CI -0.60 to -0.31, 12 studies, n=1,224), total cholesterol (−0.47 mmol/L, 95% CI -0.61 to -0.33, 15 studies, n=1,397), triglycerides (−0.32 mmol/L, 95% CI -0.44 to -0.19, 16 studies, n=1,421) and apolipoprotein B (−0.25 mg/dL, 95% CI -0.40 to -0.11, 2 studies, n=127). Berberine increased high-density lipoprotein (HDL) cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.12, 13 studies, n=1,248). Notably, the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (−0.07 mmol/L, 95% CI -0.16 to 0.02). Gastrointestinal adverse events were the most frequently reported adverse events. Conclusions Berberine decreased LDL cholesterol, triglycerides, and apolipoprotein B, with a potential sex-specific effect on HDL cholesterol. Large-scale trials considering sex disparity are required.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 16 placebo-controlled randomized trials found that oral purified berberine improves lipid profiles in adults, lowering LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B while modestly raising HDL cholesterol. The effect on HDL cholesterol appeared sex-specific, favoring women over men, though the authors call for larger trials to confirm this.
Key findings
- Berberine reduced LDL cholesterol by −0.45 mmol/L (95% CI −0.60 to −0.31; 12 studies, n=1,224), total cholesterol by −0.47 mmol/L (95% CI −0.61 to −0.33; 15 studies, n=1,397), triglycerides by −0.32 mmol/L (95% CI −0.44 to −0.19; 16 studies, n=1,421), and apolipoprotein B by −0.25 mmol/L (95% CI −0.40 to −0.11; 2 studies, n=127).
- Berberine increased HDL cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.12; 13 studies, n=1,248), with a sex-specific difference: women 0.11 mmol/L (95% CI 0.09 to 0.13) versus men −0.07 mmol/L (95% CI −0.16 to 0.02; P<0.01).
- Trim-and-fill adjustment for publication bias attenuated effects to −0.23 mmol/L (95% CI −0.42 to −0.05) for total cholesterol and −0.20 mmol/L (95% CI −0.37 to −0.03) for triglycerides.
- Gastrointestinal adverse events (constipation, diarrhea, nausea) appeared more frequent with berberine; no serious adverse events or muscle pain were reported in berberine groups. Withdrawal/discontinuation due to adverse events ranged from 2% to 6% of allocated patients in four studies.
Methods
- Study-level systematic review and meta-analysis (PROSPERO CRD42021293218) of randomized controlled trials comparing purified berberine with placebo in adults ≥18 years, excluding plant extracts, combination products, and non-placebo comparators.
- Searched MEDLINE, Embase, Wanfang, CNKI, ClinicalTrials.gov, and WHO ICTRP through December 2021, plus reference lists of prior reviews; 16 studies met eligibility (1,529 participants: 761 berberine, 768 placebo), with treatment durations of 4 to 24 weeks.
- Mean differences with 95% CIs pooled using inverse-variance random-effects models (R package meta); heterogeneity assessed with I², publication bias with funnel plots and Egger's test, and subgroup analyses by sex, trial duration, dose, and ethnicity; risk of bias via Cochrane RoB 2 and certainty via GRADE.
Limitations
- As stated by the authors: all eligible trials assessed surrogate lipid outcomes rather than cardiovascular events; follow-up was short (4–24 weeks), so long-term efficacy and safety remain unassessed; outcome reporting was potentially biased, with inconsistent reporting of lipid components and adverse events; and heterogeneity among pooled studies was high, addressed only through study-level subgroup analyses.
- Evident from the text: the sex-specific HDL finding rests on a small number of single-sex studies (one all-male study, four in women with PCOS), and the authors themselves note the possibility that greater statistical power in women rather than a true biological difference may explain the result; apoB analyses included only 2 studies (n=127).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
12 Valid · 0 Not valid · 9 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“testosterone lowers HDL cholesterol in men, which may partly explain why we did not find an increase in HDL cholesterol in men in this systematic review and meta-analysis.”
What the sources say
- Supportedcites [41] source
The Results report that higher genetically predicted testosterone was associated with lower HDL cholesterol in men. The Introduction also reports that meta-analyses of trials in men found testosterone therapy decreased HDL cholesterol. (LLM, conf=0.90)
- Supportedcites [42] 2010, Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism source
The Cardiovascular risk factors section reports significantly lower HDL cholesterol in testosterone-treated men than in controls. The Principal findings section describes the reduction as statistically significant but small. Page numbers are not provided in the supplied passages. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In our randomized controlled trial in Chinese men, berberine increased serum testosterone, whereas trials in women with polycystic ovary syndrome (PCOS) showed berberine decreased testosterone concentrations.(16-18)”
What the sources say
- Partly supportedcites [16] Zhao JV , Yeung WF , Chan YH , Vackova D , Leung JYY , Ip DKM , et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13(8). sourceExperimental — accuracy not yet measured
The Results report a statistically significant increase in testosterone when measurements at 8 and 12 weeks were analyzed together in the randomized trial of Chinese men. However, the Abstract and Conclusions describe the effect as a *possible* increase, so the unqualified claim is stronger than the paper's conclusion. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [17] source
- Not checked — no full text of the sourcecites [18] 2014, The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment, Clin Endocrinol (Oxf) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In our randomized controlled trial in Chinese men, berberine increased serum testosterone, whereas trials in women with polycystic ovary syndrome (PCOS) showed berberine decreased testosterone concentrations.(16-18)”
What the sources say
- Supportedcites [16] Zhao JV , Yeung WF , Chan YH , Vackova D , Leung JYY , Ip DKM , et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13(8). source
The Discussion reports that berberine supplementation lowered testosterone in women with PCOS in two trials. It also contrasts those findings with a possible increase in testosterone in the paper’s trial of men. No page number is provided in our copy. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [17] source
- Not checked — no full text of the sourcecites [18] 2014, The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment, Clin Endocrinol (Oxf) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was limited evidence of asymmetry for LDL and HDL cholesterol (Supplementary Figure 1B and 1D).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Consistent with previous systematic reviews, we did not identify any serious adverse events associated with berberine.(8, 10)”
What the sources say
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 33
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Findings on efficacy · p. 11
“Funnel plots showed fewer trials on the right-hand side where berberine increased TC and TG (Supplementary Figure 1A and 1C)”
§ Supplementary Material · p. 23
“Supplementary Figure 1: Trim and fill funnel plots for total cholesterol (A), LDL cholesterol (B), HDL cholesterol (C) and triglycerides (D)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract · p. 2
“apolipoprotein B (-0.25 mg/dL, 95% CI -0.40 to -0.11, 2 studies, n=127)”
§ Findings on efficacy · p. 10
“-0.25 mmol/L (95% CI -0.40 to -0.11, I 2 =82%; 2 studies, n=127 participants; low certainty; Figure 2E) for apoB”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Findings on efficacy · p. 10
“-0.45 mmol/L (95% CI 0.60 to -0.31, I 2 =80%; 12 studies, n=1,224 participants; moderate certainty; Figure 2B) for LDL cholesterol”
§ Abstract · p. 2
“lowdensity lipoprotein (LDL) cholesterol (-0.45 mmol/L, 95% CI -0.60 to -0.31, 12 studies, n=1,224)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Findings on safety · p. 11
“see Supplementary File 5 for extracted adverse event data”
§ Supplementary Material · p. 23
“Supplementary File 4 - Adverse events raw data extraction”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Synthesis methods · p. 8
“trial duration ( ≤ 12 weeks, > 12 weeks)”
§ Subgroup Analyses · p. 12
“at different treatment durations ( ≥ 12 weeks, <12 weeks; Figure 4)”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“Two reviewers assessed the risk of bias for each study using the Cochrane RoB 2 tool.(22) Risk of bias was judged as ‘low risk of bias’, ‘some concerns’, or ‘high risk’ of bias across five distinct study domains (bias arising from the randomization process, bias due to deviations from the intended interventions, bias…”
MethodThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“(20) This report adheres to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement.(21) Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) was used to manage the entire review process and deduplicate studies.”
MethodWan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 2×
“(23, 24) For studies that reported medians and interquartile ranges (IQR), we estimated the mean and SD as described in Luo and Wan.”
MethodMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.03.001 · Cited by 4,265
Luo, D., Wan, X., Liu, J., & Tong, T. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280216669183 · Cited by 4,066 · cited 2×
“(23, 24) For studies that reported medians and interquartile ranges (IQR), we estimated the mean and SD as described in Luo and Wan.”
MethodESC/EAS Guidelines for the Management of Dyslipidaemias
Reiner, Ž., Catapano, A. L., Backer, G. D. D., et al. (2013) · doi:10.1016/j.repce.2012.12.001 · Cited by 2,682
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391 · cited 2×
“2 shows records for each study).(16-18, 23, 24, 29, 31-40) All studies were conducted in young or middle-aged adults and none of the studies enrolled participants with a history of coronary artery disease or stroke.”
Background
Research works printed but not linked: 7
- Blais J , Zhao JV , Huang X. Effect of berberine compared to placebo on lipid profiles: systematic review and meta-analysis of randomized controlled trials. PROSPERO; 2021. p. CRD42021293218.
- Li M , Li J , Liu Y , Zhao Y , Qiu Y , Jia Q , et al. The influence of berberine hydrochloride on glucolipid metabolism of patients with schizophrenia (Chinese). Chinese Journal of Prevention and Control of Chronic Diseases. 2016.
- 2012, The Clinical Study of Berberine in Patients with Polycystic Ovarian Syndrome and Insulin Resistance (Chinese), Tianjin Medical Journal, 40, 3
- 2016, Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia (Chinese), Chinese Journal of Integrated Traditional and Western Medicine, 36, 681
- 2016, Effect of berberine on symptoms and glycolipid metabolism in schizophrenia patients treated with risperidone (Chinese), Journal of Tianjin Medical University, 22, 338
- 2016, Effects of berberine combined with ethinylestradiol cyproterone acetate in the treatment of obese women with polycystic ovary syndrome (Chinese), Chinese Journal of Primary Medicine and Pharmacy, 23, 837
- 2021, Effect of berberine combined with metformin on body fat distribution and liver fat content in type 2 diabetic patients with NAFLD (Chinese), Zhejiang Medicine, 43, 2327
Cited by
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572197 · Cited by 24
Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
Qi, C., Fan, D., Wang, L., Guo, L., Jiang, H., & Wang, L. (2025) · Pharmaceutical Biology · doi:10.1080/13880209.2025.2514021 · Cited by 7
Sharma, S., & Tanwar, S. S. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100576 · Cited by 4
Metadata
- Authors
- Blais, J. E., Huang, X., & Zhao, J. V.
- Affiliations
- University of Hong Kong (HK)
- Corresponding author
- Zhao, Jie V
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2022-06-21
- Volume
- 83
- Issue
- 5
- Pages
- 403-427
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W4328048052
- Semantic Scholar
- b2ca75e2bf312edec24bb1836e8ceb0b9ac18d7e
- Cited by
- 31
- References
- 33
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 4 · 2023: 2
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Drugs (publishedVersion)
- medRxiv (submittedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
- Keywords
- berberine, dyslipidemia, hypolipidemic effect, sex differences, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein B, total cholesterol, nutraceuticals, gastrointestinal adverse effects, drug safety, cardiovascular risk reduction, risk of bias assessment, quality of evidence grading, heterogeneity
- MeSH terms
- Adult, Apolipoproteins, Berberine, Cholesterol, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Triglycerides, Randomized Controlled Trials as Topic, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials. https://app.cochat.ai/papers/10.1101/2022.06.20.22276676
- The paper
- Blais, J. E., Huang, X., & Zhao, J. V. (2022). Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials. medRxiv. https://doi.org/10.1101/2022.06.20.22276676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






